Cohen Yuval 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Cohen Yuval
DirectorChief Executive Officer
Transactions
- Sale
Common Stock, par value $0.0001 per share
2024-06-14$50.17/sh−16,830$844,297→ 84,400 total - Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−7,179$303,219→ 77,221 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$30.00/sh+11,667$350,010→ 96,067 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$4.26/sh+1,770$7,540→ 86,170 total - Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.02/sh−1,770$81,456→ 84,400 total - Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−11,667$492,779→ 84,400 total - Exercise/Conversion
Options to purchase common stock
2024-06-14−12,487→ 53,831 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (12,487 underlying) - Exercise/Conversion
Options to purchase common stock
2024-06-18−1,770→ 31,057 totalExercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (1,770 underlying) - Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−2,322$98,074→ 84,400 total - Exercise/Conversion
Options to purchase common stock
2024-06-14−16,830→ 32,827 totalExercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (16,830 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$14.10/sh+16,830$237,303→ 101,230 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$4.26/sh+12,487$53,195→ 96,887 total - Sale
Common Stock, par value $0.0001 per share
2024-06-14$50.17/sh−12,487$626,425→ 84,400 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$14.10/sh+1,770$24,957→ 86,170 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$4.26/sh+2,322$9,892→ 86,722 total - Exercise/Conversion
Options to purchase common stock
2024-06-17−1,770→ 52,061 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (1,770 underlying) - Exercise/Conversion
Options to purchase common stock
2024-06-18−2,322→ 49,739 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (2,322 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$30.00/sh+9,333$279,990→ 93,733 total - Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.02/sh−9,333$429,507→ 84,400 total - Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−1,770$74,759→ 84,400 total - Exercise/Conversion
Options to purchase common stock
2024-06-17−9,333→ 11,667 totalExercise: $30.00Exp: 2024-10-22→ Common Stock (9,333 underlying) - Exercise/Conversion
Options to purchase common stock
2024-06-18−11,667→ 0 totalExercise: $30.00Exp: 2024-10-22→ Common Stock (11,667 underlying)
Footnotes (8)
- [F1]This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F6]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.
- [F7]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
- [F8]The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.